Oxidative stress and paraoxonase status for coronary artery disease in NIDDM patients

Biomedical Research

Volumn 18, Issue 1, 2007, Pages 19-23

  Shivaprakash, T M ^b   Sarkar, Purnima Dey ^a,d   Sharma, Tripti ^c   Ramprasad, N ^b   Maheshwari, R ^b  

^a MGM MEDICAL COLLEGE   (India)

^b DEVI AHILYA UNIVERSITY   (India)

^c Christian Eminent Academy   (India)

^d NONE   (India)

Author keywords

Coronary artery disease; NIDDM; Oxidative stress; Paraoxonase

Indexed keywords

ARYLDIALKYLPHOSPHATASE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MALONALDEHYDE; TRIACYLGLYCEROL;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; ENZYME ACTIVITY; FEMALE; HUMAN; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS;

EID: 33947110417     PISSN: 0970938X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025. Prevalence, numerical estimates and projection. Diabetes Care, 1998; 21: 1414-1431.
2. Ramachandran A, Snehalatha C, Viswanathan V. Burden of type 2 Diabetes and its complications - The Indian Scenario. Curr Sci 2002; 83: 1471-1476.
3. Deepa R, Arvind K and Mohan V. Diabetes and risk factors for coronary artery disease. Curr Sci 2002; 83: 1497-1505.
4. Surekha Rani H, Madhavi G, Ramachandra Rao V. Sahay BH, Jyothy A. Risk factors for coronary heart disease in type II diabetes mellitus. Ind Jour of Clin Chem 2005; 20: 75-80.
5. Maritim AC, Sanders RA, Watkins JB. Oxidative stress and antioxidants A review. J Biochem Mol Toxicol 2003; 17: 24-38.
6. Mackness MI, Mackness B, Durrington PN. Paraoxonase and coronary heart disease. Atheroscler Suppl 2002; 3: 49-55.
7. Viviana Cavalca, Giuliana Cighetti, Fabrizia Bamonti, Alessandro Loaldi, Luana Bortone et al. Oxidative stress and homocysteine in coronary artery disease. Clin Chem 2001; 47: 887-892.
8. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of preparative ultracentrifuge. Clin Chem 1972; 18: 499-501.
9. Gavino VC, Miller JS, Ikharebha SO, Milo GE, Cornwall DG. Effects of polyunsaturated fatty acids and antioxidants on lipid peroxidation in tissue cultures. J Lipid Res 1981; 22: 763-769.
10. Gan KN, Smolen A, Eckerson HW, La Du BN. Purification of human serum Paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab Dispos 1991; 19: 100-106.
11. Alejandro Gugliucci, Ricardo Hermo, Masatomi Tsuji. Lower serum Paraoxonase acitivy in type 2 diabetic patients correlates with nitrated apo-A1 levels. Clinica Chimica Acta 2006; 368: 201-202.
12. nd May 2006] (Article in Press).
13. Saxena KK. Congestive Heart Failure in Diabetes. Cardiology Today 2002; 2: 71-76.
14. Pias P, Pogue J, gstein H et al. Risk factors for AMI in Indians: a case-control study. Lancet 1996; 348: 358-63.
15. Uhl GS, Farrell PW. Myocardial infarction in young adults: risk factors and natural history. Am Heart J 1983; 105: 548-53.
16. Chen L, Chester M, Kaski JC. Clinical factors and angiographic features associated with premature coronary artery disease. Chest 1995; 108: 364-49.
17. Zimmerman FH, Cameron A, Fisher LD. Myocardial infarction in young adults: angiographic characterization, risk factors and prognosis. J Am Coll Cardiol 1995; 26: 654-61.
18. Jung HH, Choi DH, Lee SH. Serum Malondialdehyde and coronary artery disease in hemodialysis patients. Am J Nephrol 2004; 24: 537-542.
19. Polidori MC, Millan JL, Alunni G et al. Plasma lipophilic antioxidants and MDA in congestive heart failure patients: relationship to disease severity. Free Radic Biol Med 2002; 32: 148-152.
20. Ak G, Ozgonul M, Sozmen EY, Asian SL, Sozmen B. Renal cortical thickness and PON1 activity both decrease in chronic renal failure. J Nephrol 2002; 15: 144-149.
21. Mackness MI, Durrington NP, Mackness MI. Human serum Paraoxonase. Gen Pharmacol 1998; 31: 329-336.